Monoclonal antibody therapy is beginning in the clinical setting.
نویسندگان
چکیده
منابع مشابه
Heat shock factor 5 is essential for spermatogenesis in mice: Detected by a new monoclonal antibody
Objective(s): Here, we examined the function of our produced monoclonal antibody (mAb10C3) to recognize one of the most important members of the HEAT shock factor family, Hsf5, in embryonic development and in spermatogenic cells of adult mouse testis.Materials and Methods: The targeting effects of mAb10C3 were investigated by immunohisto...
متن کاملMonoclonal Antibody Therapy of Lymphoma
Köhler and Milstein, their use as a targeted therapy for cancer has been explored widely. Depending on antigen specificity, antibodies have the potential to react preferentially with tumor cells while binding to a lesser degree with normal tissues. This is in great contrast to chemotherapy (and to some degree radiotherapy), where significant toxicity results from drug exposure to various organs...
متن کامل[Monoclonal antibody therapy in hematological malignancies].
What do you do to start reading monoclonal antibody therapy in hematologic malignancies? Searching the book that you love to read first or find an interesting book that will make you want to read? Everybody has difference with their reason of reading a book. Actuary, reading habit must be from earlier. Many people may be love to read, but not a book. It's not fault. Someone will be bored to ope...
متن کاملTrends in Malignant Glioma Monoclonal Antibody Therapy
Although new passive and active immunotherapy methods are emerging, unconjugated monoclonal antibodies remain the only kind of biological preparations approved for high-grade glioma therapy in clinical practice. In this review, we combine clinical and experimental data discussion. As antiangiogenic therapy is the standard of care for recurrent glioblastoma multiforme (GBM), we analyze major cli...
متن کاملOfatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
Background: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody-dependent phagocytosis by macrophages. Apoptosis induction is another mechanism of this antibody...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Delivery System
سال: 2002
ISSN: 1881-2732,0913-5006
DOI: 10.2745/dds.17.22